Coronavirus Disease 19 (COVID-19) Pharmacologic Treatment | Zendy

Nikolina Bogdanić | Zendy; Ljiljana Lukić | Zendy; Josip Begovać | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Coronavirus Disease 19 (COVID-19) Pharmacologic Treatment

Author(s) -

Nikolina Bogdanić,

Ljiljana Lukić,

Josip Begovać

Publication year - 2021

Publication title -

infektološki glasnik

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.105

H-Index - 7

eISSN - 1848-7769

pISSN - 1331-2820

DOI - 10.37797/ig.40.4.4

Subject(s) - covid-19 , pandemic , disease , outbreak , coronavirus , medicine , virology , intensive care medicine , infectious disease (medical specialty) , pathology

Since the first cases of COVID-19 were reported from China the disease became pandemic within a few months. The viral genome was sequenced soon after the outbreak of COVID-19 which enabled development of diagnostic tests and therapeutic options. As the knowledge of SARS-CoV-2 virology increased, many potential drugs appeared. At this moment (January 12th 2021), 4426 studies of COVID-19 are registered, and more than 2680 studies are investigating therapeutic options. This is a short narrative review of currently available evidence on pharmacological treatment of COVID-19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research